home > ebr > winter 2022 > unravelling new disease biology at the interface between academia and the pharma industry


Dear guest!
To access full content of this article, please take a minute to become a member of this site. As a registered user you will be able to view all of our vast archive's material at any time. Sign up now!

       Already registered? Please sign in.

Alternatively, please use our pay-per-view service.


News and Press Releases

Orion and Amneal enter strategic partnership Ė Orion receives exclusive licence to commercialise Amnealís generic products in Europe, Australia and New Zealand

Orion Corporation today announced it has signed a long-term license agreement with Amneal Pharmaceuticals, Inc. to commercialise Amnealís generic products in Orion territories. Under the terms of the agreement, Orion is granted exclusive licence to commercialise and sell Amnealís generic products in most parts of Europe as well as in Australia and New Zealand. The initial portfolio will include a mix of generic products commercially available in the U.S. today, as well as selected pipeline products currently under development. Initial products will be registered throughout Europe, Australia and New Zealand starting in 2023, with launches expected over the coming years.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement